// App-Quantinova.ai

1014 : Reduced-Intensity Chemotherapy with Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study

Researchers

Presenter

  • Nicholas J. Short

Principal Investigators

  • Farhad Ravandi

  • Xuelin Huang

  • Nitin Jain

  • Tapan M. Kadia

  • Joseph D. Khoury

  • Jeffrey L. Jorgensen

  • Sa A Wang

  • Yesid Alvarado

  • Jan A. Burger

  • Naval Daver

  • Gautam Borthakur

  • Courtney D. DiNardo

  • Marina Konopleva

  • Naveen Pemmaraju

  • Guillermo Garcia-Manero

  • William G. Wierda

  • Steven M. Kornblau

  • Jovitta Jacob

  • Meagan Rostykus

  • Monica Kwari

  • Caitlin R. Rausch

  • Christopher Loiselle

  • Anna Milton

  • Juan Rivera

  • Rebecca Garris

  • Susan M. O'Brien

  • Elias Jabbour

Medical Centers

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Section of Nephrology, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • UCI Cancer Center, Orange, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • B-cell acute lymphoblastic leukemia

Biomarkers

  • Alanine transaminase

  • Aspartate aminotransferase

  • B-lymphocyte antigen CD20

  • Breakpoint Cluster Region

  • Creatinine

Drug/Treatment

  • Inotuzumab ozogamicin

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Blinatumomab

  • Methotrexate

  • Cytarabine liposomal

  • Rituximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved